Reminyl 4 mg/ml oral solution

Spain
Brand name Reminyl 4 mg/ml oral solution
Form solution, oral
Active substance / Dosage
Prescription type Hospital Diagnosis
Registration number 63388
Reminyl 4 mg/ml oral solution solution, oral

Package leaflet: Information for the user

Introduction

Package leaflet: information for the user

Reminyl 4 mg/ml oral solution

galantamine

Read the entire leaflet carefully before you start taking this medicine, as it contains important information for you.

  • Keep this leaflet, as you may need to read it again.
  • If you have any questions, consult your doctor or pharmacist.
  • This medicine has been prescribed for you only, and you should not give it to others, even if they have the same symptoms as you, because it may harm them.
  • If you experience any adverse effects, consult your doctor or pharmacist, even if these are adverse effects not listed in this leaflet. See section 4.

Package leaflet contents:

  1. What Reminyl is and what it is used for
  2. What you need to know before taking Reminyl
  3. How to take Reminyl
  4. Possible side effects
  5. How to store Reminyl
  6. Contents of the pack and other information

1. What Reminyl is and what it is used for

Reminyl contains the active substance “galantamine”, a dementia medication. It is used in adults to treat the symptoms of mild to moderately severe Alzheimer's disease, a type of dementia that impairs brain function.

Alzheimer's disease causes increasing memory loss, confusion, and behavioral changes, making it progressively more difficult to carry out routine daily activities.

These effects are thought to be caused by a deficiency of “acetylcholine”, a substance responsible for transmitting messages between brain cells. Reminyl increases the amount of acetylcholine in the brain and thereby helps alleviate the symptoms of the disease.

2. What you need to know before taking Reminyl

Do not take Reminyl

  • if you are allergic to galantamine or to any of the other ingredients of this medicine (listed in section 6).
  • if you have severe liver or kidney disease.

Warnings and precautions

Talk to your doctor or pharmacist before starting to take Reminyl. This medicine should only be used for Alzheimer's disease and is not recommended for other types of memory loss or confusion.

Serious adverse effects

Reminyl may cause severe skin reactions, heart problems, and seizures. You should be alert to these adverse effects while taking Reminyl. See section 4, “Be alert to serious adverse effects”.

Before starting treatment with Reminyl, your doctor should know if you have or have had any of the following conditions:

  • liver or kidney problems
  • a heart disorder (such as chest pain usually caused by physical activity, heart attack, heart failure, slow or irregular heartbeat, prolonged QTc interval)
  • changes in electrolyte levels (natural chemicals in the blood, such as potassium)
  • a peptic ulcer (stomach)
  • blockage in the stomach or intestine
  • a disorder of the nervous system (such as epilepsy or problems controlling body movements or limbs (extrapyramidal disorder))
  • a respiratory disease or infection affecting breathing (such as asthma, obstructive lung disease, or pneumonia)
  • problems with passing urine.

Your doctor will decide whether Reminyl is suitable for you or whether the dose needs to be adjusted.

Also tell your doctor if you have recently had surgery on the stomach, intestine, or bladder. Your doctor will decide whether Reminyl is suitable for you.

Reminyl may cause weight loss. Your doctor will check your weight regularly while you are taking Reminyl.

Children and adolescents

Reminyl is not recommended for use in children or adolescents.

Other medicines and Reminyl

Inform your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicine.

Reminyl must not be taken together with medicines that work in the same way. These include:

  • donepezil or rivastigmine (for Alzheimer's disease)
  • ambenonium, neostigmine, or pyridostigmine (for severe muscle weakness)
  • pilocarpine (when taken by mouth for dry eyes or dry mouth).

Some medicines may be more likely to cause adverse effects in people taking Reminyl. These include:

  • medicines that affect the QTc interval

  • paroxetine or fluoxetine (antidepressants)

  • quinidine (for irregular heartbeat)

  • ketoconazole (an antifungal)

  • erythromycin (an antibiotic)

  • ritonavir (for human immunodeficiency virus or "HIV")

  • non-steroidal anti-inflammatory painkillers (such as ibuprofen), which may increase the risk of ulcers

  • medicines for certain heart disorders or for high blood pressure (such as digoxin, amiodarone, atropine, beta-blockers, or calcium channel blockers). If you are taking medicines for an irregular heartbeat, your doctor may examine your heart using an "electrocardiogram" (ECG).

If you are taking any of these medicines, your doctor may give you a lower dose of Reminyl.

Reminyl may affect certain anaesthetics. If you are going to have surgery under general anaesthesia, inform your doctor well in advance that you are taking Reminyl.

Consult your doctor or pharmacist if you have any questions.

Pregnancy and lactation

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to become pregnant, consult your doctor or pharmacist before using this medicine.

You must not breastfeed while taking Reminyl.

Driving and operating machinery

Reminyl may cause dizziness or drowsiness, especially during the first weeks of treatment. If you are affected by Reminyl, do not drive or operate tools or machinery.

Reminyl oral solution contains methyl and propyl parahydroxybenzoates.

These may occasionally cause allergic reactions (possibly delayed).

Reminyl oral solution contains sodium

This medicine contains less than 1 mmol of sodium (23 mg) per 6 ml of Reminyl 4 mg/ml oral solution (equivalent to the maximum daily dose of Reminyl); hence, it is essentially "sodium-free".

3. How to take Reminyl oral solution

Follow exactly the instructions for administering this medicine as given by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.

How much to take

You will start treatment with Reminyl at a low dose. The usual starting dose is 4 mg (1 mL of solution), taken twice daily (a total of 8 mg per day). Your doctor will gradually increase your dose every 4 weeks or more until the most appropriate dose for you is reached. The maximum dose is 12 mg (3 mL of solution), taken twice daily (a total of 24 mg per day).

Your doctor will explain which dose you should start with and when you should increase it. If you are unsure what to do, or if you find that the effect of Reminyl is too strong or too weak, inform your doctor or pharmacist.

Your doctor needs to see you regularly to check that this medicine is working and to discuss with you how you are feeling.

If you have liver or kidney problems, your doctor may prescribe a reduced dose of Reminyl or may decide whether this medicine is suitable for you.

How to take it

Take your dose of Reminyl twice daily, in the morning and at night, with water or other liquids. Try to take Reminyl with food.

Drink plenty of fluids while taking Reminyl to stay hydrated.

The solution comes with a syringe, which allows you to draw the exact amount needed from the bottle.

Instructions for opening the bottle and using the syringe

Fig. 1: The bottle has a child-resistant cap and must be opened as follows:

  • Press down on the screw cap while turning it counterclockwise.
  • Once unscrewed, remove the cap.

Fig. 2: Insert the syringe into the bottle.

While holding the lower ring, pull the upper ring up to the mark corresponding to the number of milliliters to be administered.

Fig. 3: Hold the lower ring and remove the syringe completely from the bottle.

Empty the syringe into any non-alcoholic beverage by sliding the upper ring downward and drink immediately.

Close the bottle.

Rinse the syringe with water.

Three diagrams numbered show how to apply a neck device and how to extract or insert a piston with the hands

If you take more Reminyl than you should

In case of overdose or accidental ingestion, contact your doctor or pharmacist immediately or
call the Toxicology Information Service at: 91 562 04 20, indicating the medication and the
amount ingested. Take with you the container with any remaining solution. Signs of an overdose may include:

  • severe nausea and vomiting
  • muscle weakness, slow heartbeat, seizures, and loss of consciousness.

If you forget to take Reminyl

If you forget to take a dose, skip that dose and continue your treatment as usual with the next scheduled dose. Do not take a double dose to make up for a missed dose.

If you forget to take more than one dose, consult your doctor.

If you stop taking Reminyl

Consult your doctor before stopping treatment with Reminyl. It is important to continue taking this medicine to treat your condition.

If you have any further questions about the use of this medicine, ask your doctor or pharmacist.

4. Possible adverse effects

Like all medicines, this medicine can cause adverse effects, although not everyone will experience them.

Be alert for serious adverse effects

Stop taking Reminyl and consult a doctor or go immediately to the nearest emergency department if you experience any of the following adverse effects:

Skin reactions, including:

  • Severe rash with blisters and peeling of the skin, especially around the mouth, nose, eyes, and genitals (Stevens-Johnson syndrome).

  • Red rash covered with small pus-filled bumps that may spread over the body, sometimes with fever (acute generalized exanthematous pustulosis).

  • Rash that may cause blisters, with spots resembling small targets (erythema multiforme).

These skin reactions are rare in people taking Reminyl (may affect up to 1 in 1,000 people).

Heart problems, including changes in heartbeat (such as slow heartbeat or extra beats) or palpitations (feeling a fast or irregular heartbeat). Heart problems may be seen as an abnormal tracing on an "electrocardiogram" (ECG), and may be common in people taking Reminyl (may affect up to 1 in 10 people).

Seizures. This is uncommon in people taking Reminyl (may affect up to 1 in 100 people).

You must stop taking Reminyl and seek immediate medical help if you notice any of the adverse effects listed above.

Other adverse effects

Very common adverse effects (may affect more than 1 in 10 people):

  • Nausea and vomiting. These adverse effects are more likely to occur during the first weeks of treatment or when the dose is increased. They usually gradually disappear as the body adjusts to the medicine and typically last only a few days. If you experience these effects, your doctor may recommend drinking more fluids and may prescribe a medicine to help prevent nausea.

Common adverse effects (may affect up to 1 in 10 people):

  • Decreased appetite, weight loss
  • Seeing, feeling, or hearing things that are not present (hallucinations)
  • Depression
  • Feeling dizzy or faint
  • Tremors or muscle spasms
  • Headache
  • Feeling very tired, weak, or generally unwell
  • Feeling very sleepy and having low energy
  • Increased blood pressure
  • Abdominal pain or discomfort
  • Diarrhea
  • Indigestion
  • Falls
  • Injuries

Uncommon adverse effects (may affect up to 1 in 100 people):

  • Allergic reaction
  • Insufficient body fluids (dehydration)
  • Tingling or numbness of the skin
  • Change in taste sensation
  • Daytime sleepiness
  • Problems controlling body movements or limbs (extrapyramidal disorder)
  • Blurred vision
  • Ringing in the ears that does not go away (tinnitus)
  • Low blood pressure
  • Flushing
  • Feeling the need to vomit (nausea)
  • Excessive sweating
  • Muscle weakness
  • Increased levels of liver enzymes in the blood

Rare adverse effects (may affect up to 1 in 1,000 people):

  • Inflamed liver (hepatitis)

Reporting of adverse effects

If you experience any type of adverse effect, talk to your doctor or pharmacist, even if it is a possible adverse effect not listed in this leaflet. You may also report them directly via the Spanish Pharmacovigilance System for Human Medicines: https://www.notificaram.es/. By reporting adverse effects, you can help provide more information on the safety of this medicine.

5. Storage of Reminyl

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date stated on the label after EXP. The expiry date refers to the last day of the month indicated.

Do not freeze.

The oral solution of Reminyl must not be used more than 3 months after the bottle has been opened for the first time.

Medicines must not be disposed of via wastewater or household waste. Dispose of containers and unused medicines at the SIGRE collection point at your pharmacy. Ask your pharmacist how to properly dispose of containers and medicines you no longer need. This will help protect the environment.

6. Contents of the pack and other information

Composition of Reminyl

  • The active substance is galantamine. 1 mL of Reminyl oral solution contains 4 mg of galantamine (as hydrobromide).
  • The other components are:

Methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), purified water, sodium saccharin, and sodium hydroxide.

Appearance of the product and contents of the pack

Reminyl is a clear, colourless oral solution supplied in a 100 mL container.

The solution comes with a syringe allowing the exact required amount to be withdrawn from the bottle.

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder

Essential Pharma Limited,

Vision Exchange Building,

Triq it-Territorjals, Zone 1,

Central Business District,

Birkirkara, CBD 1070,

Malta

Manufacturer

Janssen-Pharmaceutica, N.V.

Turnhoutseweg, 30

B-2340 Beerse

Belgium

This medicinal product is authorised in the Member States of the European Union under the following names:

Austria Reminyl 4 mg/ml- orale Lösung

Belgium Reminyl 4 mg/ml, orale oplossing

Denmark Reminyl 4 mg/ml oral opløsning

Finland Reminyl 4 mg/ml oraaliliuos

France Reminyl 4 mg/ml, solution buvable

Greece Reminyl 4 mg/ml π?σιμο δι?λυμα

Ireland Reminyl 4 mg/ml oral solution

Italy Reminyl 4 mg/ml soluzione orale

  • Luxembourg Reminyl 4 mg/ml, soluté buvable

Norway Reminyl 4 mg/ml mikstur, oppløsning

Portugal Reminyl 4 mg/ml solução oral

Spain Reminyl 4 mg/ml solución oral

Sweden Reminyl 4 mg/ml oral lösning

United Kingdom (Northern Ireland) Reminyl 4 mg/ml oral solution

This leaflet was approved on: October 2021.

Detailed and up-to-date information on this medicinal product is available on the website of the Spanish Agency of Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/).